

SHAN 22-04 PUBLIC HEALTH ADVISORY

August 26, 2022

Contact: 707-784-8001 or 707-784-8005 (after-hours) **NEW FAX** 707-784-5927 CDProviderHelp@SolanoCounty.com

To: Solano County Healthcare Providers Administering Monkeypox Vaccines to Patients

From: Solano County Public Health

Update and Recommendations on 2022 Monkeypox JYNNEOS Vaccine Intradermal Administration

Globally and in the United States, supply of the Jynneos vaccine remain scarce. The standard regimen for Jynneos involves a 2-dose subcutaneous route of administration with an injection volume of 0.5 mL, given at an interval of 28 days. In the context of the current national Public Health Emergency, an alternative regimen involving intradermal (ID) administration with an injection volume of 0.1 mL may be used under an Emergency Use Authorization (EUA) issued by the Food and Drug Administration (FDA). Subsequent guidance from Centers for Disease Control and Prevention (CDC) and California Department of Public Health (CDPH), endorses the intradermal administration of Jynneos to maximize the number of available doses and overall risk reduction of severe monkeypox.

Actions for Providers:

- **Contact Solano County Medical and Health Operational Area Coordinator (MHOAC)** by emailing HSSResponds@solanocounty.com to request allocations of monkeypox vaccines.
- **Assess and screen patients'** medical history to determine route and dose.
 - **Intradermal (ID) administration** is recommended for patients **18 years of age and older**.
 - Patients **under 18 years old** and/or have a **history of developing keloid scars** should receive the monkeypox vaccine through **subcutaneous route**. Please contact your agency's specific legal counsel for more guidance on consent for minors.
- **Utilize low dead space syringes and needles**, for intradermal injection to maximize the number of available doses and overall risk reduction of severe monkeypox.
- **Train vaccinators** on proper intradermal injection techniques to minimize inadvertent underdosing or leakage, which could reduce level of antibody generated by a dose and require revaccination.
 - [Jynneos Intradermal Administration Video \(CDC\)](#)
 - [FDA EUA Fact Sheet for Healthcare Providers](#)
- **Provide patients** a copy of the current [Vaccine Information Statement \(VIS\)](#) ([Spanish VIS](#)).
- **Educate and counsel patients** about possible side effects from vaccination including pain, redness, swelling, induration, and itching at the injection site. Prolonged duration of induration or erythema at the injection site is likely to occur following ID administration ([Jynneos Vaccination Patient Counseling](#)).
- **Ensure** data on all Jynneos doses administered are uploaded to the California Immunization Registry (CAIR) **within 24 hours of administration**.

Additional Resources:

1. [CDPH Interim Guidance for Intradermal Administration of Jynneos](#)
2. [CDC Standing Orders for Intradermal Administration \(Alternative Dosing Regimen\)](#)
3. [CDC Standing Orders for Subcutaneous Administration \(Standard Regimen\)](#)
4. [CDC Jynneos Vaccine](#)
5. [CDC Jynneos Vaccine Administration Errors and Deviations](#)
6. [EZIZ Monkeypox Intradermal Vaccination Training Resources](#)

275 Beck Avenue, P.O. Box 4090, MS 5-240, Fairfield, CA 94533-6804, tel/707 784 8600, fax/707 784-5927